Active	Status	Sponsor type	Region	Phase	Filter
8 Active 4 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Giordano, Monica
IOLANTHE, NCT06121401: First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients	Recruiting	4	190	Europe	Olaparib, Lynparza, Bevacizumab	Mario Negri Institute for Pharmacological Research, AstraZeneca	Carcinoma, Ovarian Epithelial	03/27	09/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Giordano, Monica
IOLANTHE, NCT06121401: First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients	Recruiting	4	190	Europe	Olaparib, Lynparza, Bevacizumab	Mario Negri Institute for Pharmacological Research, AstraZeneca	Carcinoma, Ovarian Epithelial	03/27	09/27